# Chondrogenesis of Peripheral Blood-Derived Mesenchymal Stromal Cells

## TL;DR

Peripheral blood-derived mesenchymal stromal cells can effectively form cartilage in lab settings and show promise for cartilage repair in clinical applications.

## Contribution

The study highlights PB-MSCs as a minimally invasive and clinically viable alternative for cartilage regeneration.

## Key findings

- PB-MSCs demonstrate robust chondrogenic differentiation in 3D culture systems.
- Intra-articular administration of PB-derived cells combined with hyaluronic acid supports cartilage repair.
- Biomaterials like PEG-CRGD hydrogels enhance PB-MSC adhesion and chondrogenesis.

## Abstract

What are the main findings?
Peripheral blood-derived mesenchymal stromal cells (PB-MSCs) exhibit typical MSC immunophenotypes and demonstrate robust chondrogenic differentiation in vitro, particularly in 3D culture systems.Preclinical and early clinical evidence suggest that intra-articular administration of PB-derived cell-based approaches (often combined with hyaluronic acid (HA)) supports cartilage repair, and biomaterial strategies may further enhance cell adhesion and chondrogenesis.

Peripheral blood-derived mesenchymal stromal cells (PB-MSCs) exhibit typical MSC immunophenotypes and demonstrate robust chondrogenic differentiation in vitro, particularly in 3D culture systems.

Preclinical and early clinical evidence suggest that intra-articular administration of PB-derived cell-based approaches (often combined with hyaluronic acid (HA)) supports cartilage repair, and biomaterial strategies may further enhance cell adhesion and chondrogenesis.

What are the implications of the main findings?
PB-MSCs represent a minimally invasive, clinically attractive cell source for cartilage repair, with potential to broaden access to regenerative approaches.Standardisation of PB-MSC isolation, characterisation, and delivery protocols is essential to reduce variability and enable reliable clinical translation.

PB-MSCs represent a minimally invasive, clinically attractive cell source for cartilage repair, with potential to broaden access to regenerative approaches.

Standardisation of PB-MSC isolation, characterisation, and delivery protocols is essential to reduce variability and enable reliable clinical translation.

Articular cartilage, a highly specialised and avascular tissue, exhibits limited regenerative potential following trauma or degenerative conditions such as osteoarthritis (OA). Conventional surgical interventions, including microfracture and autologous chondrocyte implantation (ACI), have shown limited long-term efficacy due to donor site morbidity and restricted cell proliferation. In this context, mesenchymal stromal cells (MSCs) have emerged as a promising alternative owing to their multipotency, self-renewal capacity, and low immunogenicity. While bone marrow (BM) remains the traditional source of MSCs, recent studies have reported that peripheral blood-derived mesenchymal stromal cells (PB-MSCs) may possess chondrogenic, osteogenic, and adipogenic potential comparable to that of BM-derived MSCs. PB-MSCs can be harvested through minimally invasive methods, thereby avoiding the complications associated with BM aspiration. Experimental evidence indicates that PB-MSCs exhibit strong cell viability, proliferative potential, and the ability to synthesise cartilage-specific extracellular matrix proteins, such as type II collagen and sulphated glycosaminoglycans, within three-dimensional scaffolds. Immunophenotypically, PB-MSCs express mesenchymal markers including CD29, CD44, CD90, and CD105 while lacking hematopoietic markers CD34 and CD45. Flow cytometry analyses reveal that CD105+ populations increase following cryopreservation, highlighting their clinical utility. In contrast to these experimentally defined PB-MSCs, the term peripheral blood stem cells (PBSCs) is used in clinical studies to describe heterogeneous, non-cultured peripheral blood-derived cell preparations, typically enriched in hematopoietic stem and progenitor cells following granulocyte colony-stimulating factor (G-CSF) mobilisation, without full mesenchymal characterisation. In vitro studies confirm successful tri-lineage differentiation, whereas in vivo investigations have demonstrated effective cartilage regeneration using PB-based clinical approaches, including postoperative intra-articular administration of hyaluronic acid (HA) combined with PBSCs, as well as implantation of PBSCs covered with a collagen membrane. Furthermore, advancements in biomaterial engineering, such as poly(ethylene glycol)–cysteine–arginine–glycine–aspartic acid (PEG-CRGD) hydrogels, have enhanced PB-MSC adhesion, proliferation, and chondrogenic differentiation while promoting immunomodulation through M2 macrophage polarisation. Despite these promising outcomes, the available evidence remains limited and heterogeneous, with substantial variability in cell definitions, experimental models, and clinical study designs, which currently constrains definitive conclusions regarding clinical efficacy. Future research should focus on optimising isolation protocols, understanding molecular pathways governing PB-MSC chondrogenesis, and standardising clinical applications. Overall, PB-MSCs represent a viable, less invasive, and translationally relevant cell source for cartilage regeneration and regenerative orthopaedic therapies